| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales, net | 10,107 | 11,280 | 12,689 | 13,045* |
| Cost of sales | 10,383 | 11,251 | 11,670 | 11,828* |
| Gross (loss) profit | -276 | 29 | 1,019 | 1,217* |
| Selling and administrative expenses | 809 | 943 | 856 | 1,003* |
| Operating (loss) income | -1,085 | -914 | 163 | 214* |
| Interest income, net | -39 | -40 | -33 | -10* |
| Other income, net | 11 | 0 | NaN | -85* |
| Other income, net | 50 | 40 | NaN | -75* |
| (loss) income before income taxes | -1,035 | -874 | 196 | 139* |
| Income tax (benefit) expense, net | -198 | -112 | 73 | 636* |
| Net (gain) income | -837 | -762 | 123 | -497 |
| Basic EPS | -0.03 | -0.03 | 0 | -0.016 |
| Diluted EPS | -0.03 | -0.03 | 0 | -0.016 |
| Basic Average Shares | 31,059,610 | 31,059,610 | 31,059,610 | 30,486,635 |
| Diluted Average Shares | 31,059,610 | 31,059,610 | 31,421,338 | 31,340,548 |
INTEGRATED BIOPHARMA INC (INBP)
INTEGRATED BIOPHARMA INC (INBP)